<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We determined the dose response of the <z:chebi fb="13" ids="16761">ADP</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (0.3-50 mg/kg p.o.) in rat models of <z:mp ids='MP_0005048'>thrombosis</z:mp> and provoked <z:mp ids='MP_0001914'>bleeding</z:mp> and correlated these activities to ex vivo platelet activation </plain></SENT>
<SENT sid="1" pm="."><plain>Carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> was induced by FeCl(2) </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> time was measured by mesenteric vessel puncture and renal cortex or cuticle incision </plain></SENT>
<SENT sid="3" pm="."><plain>Platelet biomarkers included standard <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced aggregation, P2Y(12) receptor occupancy, and phosphorylation of <z:chebi fb="1" ids="35620">vasodilator</z:chebi>-stimulated phosphoprotein </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> decreased <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight up to 78%, caused maximal prolongation of cuticle and mesenteric <z:mp ids='MP_0001914'>bleeding</z:mp>, but had little effect on renal bleeds </plain></SENT>
<SENT sid="5" pm="."><plain>Due to the steep mesenteric dose response, further comparisons concentrated on cuticle <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The half-maximal inhibitory dose (ED(50)) for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> reduction was 2.4 +/- 0.4 mg/kg, with 10 mg/kg providing optimal blood flow preservation and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> reduction </plain></SENT>
<SENT sid="7" pm="."><plain>The ED(50) for <z:mp ids='MP_0001914'>bleeding</z:mp> was 10.5 +/- 3.4 mg/kg </plain></SENT>
<SENT sid="8" pm="."><plain>Increased <z:mp ids='MP_0001914'>bleeding</z:mp> was intermediate (3-fold) at 10 mg/kg and maximal (6-fold) at 30 mg/kg </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> biomarkers were affected, but with differing sensitivity </plain></SENT>
<SENT sid="10" pm="."><plain>ED(50)s for peak platelet aggregation to 10 microM <z:chebi fb="13" ids="16761">ADP</z:chebi> (11.9 +/- 0.4 mg/kg) and the <z:chebi fb="1" ids="35620">vasodilator</z:chebi>-stimulated phosphoprotein index (16.4 +/- 1.3 mg/kg) approximated the higher ED(50) for <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>ED(50)s for ligand binding (3.0 +/- 0.3 mg/kg) and late aggregation (5.1 +/- 0.4 mg/kg) better matched the lower ED(50) for antithrombotic activity </plain></SENT>
<SENT sid="12" pm="."><plain>Aspirin exerted lesser effects on <z:mp ids='MP_0001914'>bleeding</z:mp> (42-70% increase in <z:hpo ids='HP_0000001'>all</z:hpo> models) and <z:mp ids='MP_0005048'>thrombosis</z:mp> (24% inhibition) </plain></SENT>
<SENT sid="13" pm="."><plain>In summary, antithrombotic doses of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> have limited effects on <z:mp ids='MP_0001914'>bleeding</z:mp> and standard measures of platelet aggregation </plain></SENT>
<SENT sid="14" pm="."><plain>Other biomarkers may be more sensitive for tracking antithrombotic efficacy </plain></SENT>
</text></document>